Drug Profile
Research programme: HIV protease inhibitors - Roche
Latest Information Update: 09 Nov 2006
Price :
$50
*
At a glance
- Originator Roche
- Class Small molecules
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 09 Nov 2006 Discontinued - Preclinical for HIV infections treatment in United Kingdom (unspecified route)
- 06 May 2001 New profile
- 06 May 2001 Preclinical development for HIV infections treatment in United Kingdom (Unknown route)